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Abstract
Purpose: Multiple myeloma is a hematologic malignancy originating from clonal plasma cells. Despite effective
therapies, outcomes are highly variable suggesting marked disease heterogeneity. The role of functional imaging for
therapeutic management of myeloma, such as positron emission tomography with 2-deoxy-2-[18F]fluoro-D-glucose
(18F-FDG-PET), remains to be determined. Although some studies already suggested a prognostic value of 18F-FDG-
PET, more specific tracers addressing hallmarks of myeloma biology, e.g. paraprotein biosynthesis, are needed. This
study evaluated the amino acid tracers L-methyl-[11C]-methionine (11C-MET) and [18F]-fluoroethyl-L-tyrosine (18F-Fet)
for their potential to image myeloma and to characterize tumor heterogeneity.
Experimental Design: To study the utility of 11C-MET, 18F-Fet and 18F-FDG for myeloma imaging, time activity
curves were compared in various human myeloma cell lines (INA-6, MM1.S, OPM-2) and correlated to cell-biological
characteristics, such as marker gene expression and immunoglobulin levels. Likewise, patient-derived CD138+
plasma cells were characterized regarding uptake and biomedical features.
Results: Using myeloma cell lines and patient-derived CD138+ plasma cells, we found that the relative uptake of 11C-
MET exceeds that of 18F-FDG 1.5- to 5-fold and that of 18F-Fet 7- to 20-fold. Importantly, 11C-MET uptake significantly
differed between cell types associated with worse prognosis (e.g. t(4;14) in OPM-2 cells) and indolent ones and
correlated with intracellular immunoglobulin light chain and cell surface CD138 and CXCR4 levels. Direct comparison
of radiotracer uptake in primary samples further validated the superiority of 11C-MET.
Conclusion: These data suggest that 11C-MET might be a versatile biomarker for myeloma superior to routine
functional imaging with 18F-FDG regarding diagnosis, risk stratification, prognosis and discrimination of tumor
subtypes.
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Introduction
Multiple myeloma (MM), classified as a post-germinal center
Non-Hodgkin`s lymphoma, is a hematological neoplasm
originating from plasma cells. MM accounts for approximately
1% of all cancers and around 10% of hematological
malignancies [1,2]. Despite recent advent of new therapeutics
enabling more durable partial or complete remissions, almost
all patients eventually relapse and die from their disease. A
critical question remains whether - not yet clearly defined -
subgroups of patients can benefit from more aggressive
therapies. Due to high inter- and intra-patient tumor
heterogeneity, identification of molecular lesions driving
myeloma in individual patients is essential for the development
of novel therapeutic algorithms [3-5]. Besides planar x-ray, the
role of imaging for therapeutic management of MM and risk
stratification remains to be determined. Several studies have
demonstrated the usefulness of positron emission tomography
(PET) using the radiolabeled glucose analog 2-deoxy-2-
[18F]fluoro-D-glucose (18F-FDG) for diagnosis, staging and
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prognostication, leading to implementation into the revised
Salmon/Durie staging system (Salmon/Durie PLUS) [6-10].
However, 18F-FDG PET has limited sensitivity and specificity:
glucose uptake in inflammatory lesions can lead to false
positive findings; the generally low metabolic activity of MM
might account for false negative results, especially in case of
diffuse bone marrow involvement [11]. MM is characterized by
excess production of aberrant immunoglobulins (M-protein).
Therefore, radiotracers addressing paraprotein biosynthesis
and/or amino acid transport might serve as surrogate markers
reflecting metabolic activity of the disease and, hence, prove
useful for assessing response to therapy and prognosis in
individual patients.
This study aimed at evaluating the amino acid tracers L-
methyl-[11C]-methionine (11C-MET) and [18F]-fluoroethyl-L-
tyrosine (18F-FET) for their potential to characterize MM lesions
non-invasively. Time activity curves of 11C-MET, 18F-FET and
18F-FDG were compared in various human myeloma cell lines
and correlated to hallmarks of MM biology, including levels of
immunoglobulin (Ig) light chains, proliferation rate, as well as
CD138 and CXCR4 expression. In a more physiological model,
primary CD138+-plasma cells were analyzed regarding
retention of imaging biomarkers. Uptake patterns were
correlated to biomedical features of individual patient samples.
Our data suggest that 11C-MET represents a versatile imaging
biomarker for MM with the potential to specifically detect MM
lesions using PET and to discriminate tumor subtypes.
Materials and Methods
Ethics statement
All experiments involving human material were approved by
the ethics committee of the University Wuerzburg (#192/12).
Bone marrow biopsies from patients diagnosed with MM were
taken after obtaining informed written consent from each
patient.
Cell culture
The human myeloma cell line INA-6 [12] was a gift from the
Dept. of Hematology, University Hospital Wuerzburg. OPM-2
(DSMZ no. ACC50) cells were purchased from the German
Collection of Microorganisms and Cell Culture (DSMZ,
Braunschweig, Germany) and MM.1S (ATCC no. CRL-2974)
were obtained from LGC Standards (Wesel, Germany). Cell
lines were cultured in Roswell Park Memorial Institute Medium
1640 (supplemented with 10% FCS, 2mM L-glutamine, 1mM
sodium pyruvate, 100 U/mL penicilline and 100 µg/mL
streptomycine; all media and supplements: Invitrogen,
Darmstadt, Germany) at 37 °C in a 5% CO2, humidified
atmosphere. Additionally, 2.7 ng/mL hrIL-6 (Miltenyi, Bergisch-
Gladbach, Germany) were added to cultures of INA-6 cells.
Cell line identity was confirmed at the DSMZ (July 2013) by
testing for the expression of eight different short tandem repeat
loci according to the guidelines for authentication of human cell
lines and, additionally, by examining for presence of rodent
mitochondrial DNA sequences. Regular testing of cell cultures
using the Venor GeM Mycoplasma Detection Kit (Sigma-
Aldrich, Taufkirchen, Germany) ensured absence of
contamination with mycoplasma.
Isolation of CD138+-plasma cells
CD138+-plasma cells were isolated from bone marrow
aspirates of 19 patients diagnosed with MM by Ficoll density
gradient centrifugation (density 1.007; Sigma-Aldrich,
Taufkirchen, Germany) and positive selection using CD138+-
micro beads and MACS technology (Miltenyi, Bergisch-
Gladbach, Germany) after obtaining informed written consent.
Purity of isolated cells was controlled by flow cytometry using
an anti-hCD138+-APC antibody (Miltenyi, Bergisch-Gladbach,
Germany). Isolated cells were diluted in PBS to a defined
concentration and directly analyzed in uptake experiments.
Flow cytometric analyses
Single cell suspensions were stained with fluorochrome
conjugated antibodies against hCD138+-APC (Syndecan; clone
B-B4) or hCXCR4-PE (hCD184; clone 12G5; Miltenyi,
Bergisch-Gladbach, Germany) and analyzed with a BD
FACSCalibur flow cytometer using the BD CellQuest software
(Beckton Dickinson, Heidelberg, Germany). Intracellular
staining of immunoglobulin kappa and lambda light chains was
performed using anti-hIg kappa light chain-APC (clone
IS11-24D5) and anti-hIg lambda light chain-FITC (clone
IS7-24C7) antibodies with the Inside Stain Kit from Miltenyi
(Bergisch-Gladbach, Germany) according to the manufacturer's
instructions.
Cell proliferation assay
Cells were seeded at a density of 1*105 cells per well in a 96-
well plate in triplicates, grown for 48 h and were subsequently
fixed with 70% ethanol. After overnight storage at 4 °C, cells
were washed and stained with rabbit-anti-hKi67-FITC antibody
(clone SP6; abcam, Camebridge, UK) according to the
manufacturer's instructions. Geometric mean fluorescent
activity (GeoMean) of samples was quantified with a BD
FACSCalibur flow cytometer using the BD CellQuest software
(Beckton Dickinson, Heidelberg, Germany) and corrected for
background staining.
Synthesis of 18F-FDG, 18F-FET and 11C-MET
Radiopharmaceuticals were produced in house with a 16
MeV Cyclotron (GE PETtrace 6; GE Healthcare, Milwaukee,
USA). 18F-FDG was synthesized using GE FASTlab
methodology according to the manufacturer‘s instructions. 18F-
FET was synthesized on a GE TRACERlab FX-FN as
previously described by Bourdier et al. [13]. 11C-MET was
synthesized on a GE TRACERlab FX-C Pro by on-column 11C-
methylation of L-homocysteine with 11CH3I according to the
procedures described by Kniess [14] and Gomzina and co-
workers [15]. Before use, radiochemicals were analyzed by
HPLC for radiochemical identity and purity.
Cellular uptake experiments
Sub-confluent cell cultures were harvested and adjusted to a
concentration of 400.000 cells/ 500 µL PBS per sample.
Imaging Biomarker for Multiple Myeloma
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Radioactive substances were diluted to 1*106 counts per
minute (cpm)/ 50 µL PBS. After addition of 1*106 cpm, samples
were incubated for various times up to 120 min at 37 °C. Tracer
uptake was stopped by incubation on ice, followed by washing
twice with PBS to remove residual radioactivity. Intracellular
radioactivity was quantified using a semi-automated gamma-
counter (Wallac 1480-Wizard, Perkin Elmer, Rodgau,
Germany). All samples were measured in triplicates.
Background activity- and decay-corrected data were expressed
counts per minute (cpm) per 1000 cells.
Statistical analysis
Statistical significance was assessed using Kruskal-Wallis-
testing and posthoc analysis. A p-value of <0.05 was
considered to be statistically significant. Analysis of correlation
was done according to Pearson.
Results
Hallmarks of MM biology in myeloma cell lines
To reflect MM heterogeneity, MM cell lines with different
clinical and cell-biological characteristics were selected (table
1). Cell lines were analyzed regarding hallmarks of MM
pathology, such as proliferation rate, cell surface expression of
CD138 and of CXCR4. The proliferative capacity, as assessed
by flow cytometric Ki67-staining, differed significantly (p <0.05)
between MM1.S versus OPM-2 and INA-6 cells, with the latter
two growing roughly 2.5-times faster (Figure 1A). CXCR4, a
homing factor for myeloma cells, was most abundant on
OPM-2 cells; in contrast, INA-6 expressed only half as much
CXCR4 and MM1.S cells approximately seven times less
(Figure 1B). Quantification of the adhesion molecule CD138
revealed high cell surface levels on OPM-2 cells and markedly
lower expression on MM1.S and INA-6 (Figure 1C).
Intracellular immunoglobulin light chain levels
As MM is characterized by excess production of aberrant
immunoglobulins, intracellular levels of kappa and lambda light
chains were evaluated. In agreement with their origin (table 1),
INA-6 cells stained positive for Ig kappa light chains, while all
other cell lines produced Ig lambda light chains. Flow
cytometric quantification demonstrated varying intracellular
abundance of the respective light chains with increasing levels
from INA-6 to MM1.S and OPM-2 cells (1 : 2 : 4; Figure 2).
Uptake of 11C-MET and 18F-FET by MM cell lines in
comparison to 18F-FDG
18F-FDG-PET is of value for the detection of MM-lesions, but
radiotracers addressing the characteristic paraprotein
biosynthesis might be more appropriate to reflect metabolic
activity of the disease. Maximum uptake of 18F-FDG
approximated 70-100 cpm/1000 cells in all cell lines and was
reached after 30 min (INA-6) or 60 min (OPM-2, MM.1S),
respectively. Thereafter, slightly decreasing radiotracer
retention was observed (Figure 3A).
Levels of intracellular 18F-FET were significantly lower than
those of 18F-FDG, with a maximum level of ~20 cpm/1000 cells
(Figure 3B). Efflux of 18F-FET occurred rapidly. The highest
retention was observed for 11C-MET and ranged between 144
cpm/1000cells for MM1.S cells (45 min), 232 cpm/1000cells for
INA-6 (30 min) and 422 cpm/1000cells for OPM-2 cells (45
min). Already after 5 minutes post tracer application, relative
uptake of 11C-MET exceeded maximal 18F-FDG retention
drastically. Interestingly, 11C-MET levels discriminated two
groups: methionine-uptake by OPM-2 cells was significantly
higher than by INA-6 and MM.1S cells (Figure 3C).
Validation of 11C-MET, 18F-FET and 18F-FDG as surrogate
markers of MM biology in CD138+-plasma cells
Next we set out to validate our findings using patient-derived
MM cells (table 2). The strongly limited cell number in most
samples only permitted single time point analyses. Whenever
cell number allowed, cells isolated from one patient were split
and one half was incubated for 60 min with either 11C-MET
(patients no. 13, 16, 17, 18, 19, 21, 22, 26) or 18F-FET (patients
no 7, 10, 11), whereas the second half was incubated with 18F-
FDG for direct comparison between test and standard tracer. In
agreement with the results in established cell lines, the amount
of 18F-FET retained by primary MM-cells after 60 min tended to
be less than that of 18F-FDG (Figure 4A). However, direct intra-
sample comparison did not reveal clear differences between
18F-FET- and 18F-FDG-retention. Contrarily, primary MM cells
had a markedly enhanced capacity to take up 11C-MET (Figure
4A). This latter finding was especially intriguing when directly
comparing 18F-FDG and 11C-MET data (Figure 4B).
Furthermore, higher 11C-MET retention in a sample tended to
be accompanied by higher free immunoglobulin light chain
levels (r = 0.509), but not by altered expression of Ki-67 (r=
0.033; Figure S1A+B). Together, these data underline the
Table 1. Characteristics of MM-cell lines reflect tumor heterogeneity.
cell line INA-6 MM1.S OPM-2
reference Burger (1994) ARCC CRL-2974 DSMZ ACC50
species human human human
diagnosis MM MM MM
Ig IgG κ IgA λ IgG λ
growth suspension partially adherent suspension
misc. IL-6 dependent dexamethasone sensitive t(4;14) hypertriploid
doi: 10.1371/journal.pone.0084840.t001
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notion of 11C-MET being a promising marker for myeloma-
imaging.
Discussion
Despite limited sensitivity and specificity, whole body x-ray is
still considered as standard imaging test for detecting bone
disease. The role of functional imaging in this scenario has not
been clearly defined yet [6,16]. There is a growing body of
evidence though that molecular imaging techniques, such as
dynamic contrast-enhanced magnetic resonance imaging
(MRI) or PET/computed tomography (PET/CT), might prove
beneficial for discriminating active lesions from indolent ones,
for assessment of treatment response and for therapeutic
management of MM [7,8,10,17-22]. 18F-FDG-PET/CT has even
been described as an emerging modality for imaging patients
with multiple myeloma by the International Myeloma Working
Group (IMWG). However, the concept of increased glucose
metabolism as a surrogate for myeloma viability is hampered
by non-specific retention of 18F-FDG in inflammatory lesions
and reduced sensitivity in diffuse bone marrow infiltration.
Moreover, several functional imaging approaches might be
needed to accurately reflect tumor heterogeneity in MM
[6,11,18].
In this study assessing the utility of alternative, potentially
more specific imaging biomarkers for PET imaging, we have
demonstrated a significantly higher retention of the
radiolabeled amino acid 11C-MET in biologically diverse
myeloma cells. In established cell lines, uptake of 11C-MET
exceeded maximal 18F-FDG retention already after short
incubation time and reached an approximately 1.5- to 5-fold
higher uptake as compared to 18F-FDG and other tracers
studied. Our data suggest that PET using 11C-MET as
surrogate marker for paraprotein biosynthesis and amino acid
Figure 1.  Hallmarks of MM-biology in MM-cell lines.  (A) Proliferation rate. Cells were stained with anti-hKi67 FITC antibody and
geometric mean fluorescent intensity (GeoMean) was quantified by FACS. All samples were analyzed in duplicates and background
corrected (n=4). Cell surface expression of CXCR4 (B) and CD138+ (C) was analyzed by FACS. Cells were stained with an anti-
hCXCR4-PE or anti- hCD138-APC antibody in duplicate, background-corrected and GeoMean was quantified (n=5). Columns
represent mean values and error bars the standard deviation. Asterisk indicate statistically significant differences (p <0.05).
doi: 10.1371/journal.pone.0084840.g001
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turnover may outperform the current practice of imaging MM
glucose use. These findings were recapitulated in primary MM
cells derived from patients, providing further evidence of the
utility of the proposed approach for MM imaging.
Imaging paraprotein biosynthesis as read-out for viable
myeloma lesions is supported by two recently published pilot
clinical trials reporting an equal or even greater number of
lesions in patients with plasma cell malignancies detected by
11C-MET-PET, as compared to 18F-FDG-PET [23,24]. Together,
these encouraging results warrant larger prospective clinical
trials to corroborate the initial findings and to further investigate
the clinical value of 11C-MET-PET in non- or oligo-secretory
myelomas as well as in the setting of dedifferentiated
extramedullary disease. Furthermore, due to higher retention in
myeloma cells, 11C-MET might prove useful for the detection of
diffuse bone marrow involvement, a setting which is known as
a weakness of 18F-FDG-PET imaging [16].
Importantly, in our study two distinct groups of cell lines
could be discriminated on basis of 11C-MET retention:
enhanced 11C-MET uptake tended to match with higher levels
of intracellular immunoglobulin light chains, higher CD138 and
CXCR4 expression on the cell surface and presence of
cytogenetic aberrations associated with worse prognosis
(t(4;14) in OPM-2). As immunoglobulin synthesis is a hallmark
of MM, increased 11C-MET retention might thus be explained
by at least partial incorporation into (para-) proteins, as has
been shown for other tumor entities [25,26]. Molecules
mediating the interaction between myeloma cells and bone
marrow stromal cells, immunoglobulin levels and cytogenetic
alterations are important determinants of myeloma pathology
and serve as markers for disease activity and/or
aggressiveness [27-31]. Based on this, the potential
association of CD138, CXCR4 and intracellular
immunoglobulins with 11C-MET uptake we found here, might
allow for non-invasive risk stratification of the individual patient
and response monitoring using imaging with PET/CT. Our data
further suggest that relative 11C-MET uptake might be able to
reflect myeloma tumor biology and, hence, might facilitate
assessment of myeloma heterogeneity and discrimination of
tumor subtypes.
The precise role of CD138 and CXCR4 in myeloma
pathology and management remains to be determined though.
With the introduction of very specific, targeted radiotracers,
such as radiolabeled antibodies or artificial ligands (e.g.
CXCR4 antagonists [32,33] or anti-CD138 antibodies [34,35]),
these two factors present interesting targets for further
research and potential theranostic applications [35-39]. As
CXCR4 expression regulates myeloma cell homing and has
very recently been linked to MM prognosis [40], this marker
might further be useful for discriminating intra- and
extramedullary MM lesions [41].
Although our data suggest that more aggressive cells with a
high uptake of 11C-Methionine feature a higher proliferation rate
and higher levels of intracellular immunoglobulin light chains
(OPM-2), the alternate hypothesis, that a reduction of
immunoglobulin production is accompanied by enhanced
Figure 2.  Immunoglobulin κ/λ light chain levels.  Intracellular levels of either λ- (MM1.S, OPM-2) or κ- (INA-6) immunoglobulin
light chains were determined by FACS analysis (GeoMean) using anti-Ig λ-FITC- and anti-Ig κ-APC antibodies. Background-
corrected means ± standard deviation are shown (n=7). Asterisk indicate statistically significant differences (p <0.05).
doi: 10.1371/journal.pone.0084840.g002
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proliferation in more aggressive myelomas, is plausible as well.
Accordingly, we found a partial connection of immunoglobulin
levels and 11C-MET uptake in patient-derived primary cells, but
there was no statistically significant correlation. When
comparing patients diagnosed with MGUS (patients no. 2, 3) to
patients with aggressive symptomatic myeloma (translocation
t(4;14); patients no. 1, 20), degree of bone marrow infiltration
and Ki-67 index are lower in MGUS, but none of the other
parameters described distinguishes between the asymptomatic
precursor form and full-blown myeloma (table S1). Based on
the data shown here this conflict cannot be unequivocally
answered, particularly due to the limited sample size of our
study. It also has to be considered that multiple myeloma is a
very heterogenous disease. Attempts to stratify myeloma
patients into risk groups have hardly been successful so far.
Therefore it is conceivable that there simply is no general
pattern characterizing a certain type of myeloma, but many
different individual presentations in a longitudinal follow-up,
underlining the need for individualized patient management.
It can be speculated that the minimal cell uptake of 18F-FET,
as observed in our study, is due to its less efficient transport
into cells caused by the 18F-linker. Furthermore, myeloma cells
predominantly express the large amino acid transporter 1
(LAT1) and tyrosine preferentially enters cells via LAT2 [42].
Although the underlying pathophysiological mechanism
remains unclear, 18F-FET does not seem to be a promising
candidate biomarker in myeloma imaging.
In conclusion, 11C-MET might be superior to 18F-FDG
regarding detection of active myeloma lesions. The higher
sensitivity of 11C-MET could prove useful to overcome
limitations of standard 18F-FDG-PET/CT including detection of
minimal bone marrow infiltration, diffusely disseminated
intramedullary disease and/or detection of myeloma cells with
just marginally increased metabolism. The possibility of a
connection between 11C-MET uptake and intracellular
immunoglobulin light chain, CD138 and CXCR4 levels raises
potential for patient risk stratification, response monitoring and
treatment individualization.
Figure 3.  Uptake of 11C-MET and 18F-FET by MM-cell lines in comparison to 18F-FDG.  Intracellular radioactivity following
incubation with 18F-FDG (A), 18F-FET (B) or 11C-MET (C) was quantified using a gamma-counter. Relative uptake of background-
and decay-corrected triplicate-samples was expressed as cpm per 1000 cells (mean ± sem; n=5).
doi: 10.1371/journal.pone.0084840.g003
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Table 2. Patient characteristics.
Patient no. age sex  diagnosis  Ig DS stage initial diagnosis cytogenetic alterations
1 69 ♀ MM κ light chains IIIB 06/2012 del13q; t(4;14)
2 61 ♂ MGUS n.d. n.d. 2012 n.d.
3 73 ♀ MGUS IgG κ n.d. n.d. n.d.
4 70 ♀ MM IgA λ II A 01/2011 n.d.
5 80 ♂ MM IgG κ I 07/2012 n.d.
6 41 ♂ MM IgG κ IIA 12/2011 hyperdiploid
7 55 ♂ MM IgG κ n.d. 08/2012 normal
9 71 ♀ MM IgG κ III A 12/2011 del13q
10 62 ♂ MM IgA λ III A n.d. hyperdiploid
11 64 ♂ MM IgG κ III A 08/2012 del13q
12 62 ♂ MM IgG κ IIIA 10/2012 normal
13 76 ♂ MM IgG λ III A 10/2003 normal
14 64 ♂ MM IgA κ IA 12/2002 del13q
15 73 ♂ MM IgG κ IIIA 07/2006 del13q; t(11;14)
16 77 ♂ MM λ light chains n.d. 06/2008 n.d.
17 65 ♀ MM IgG λ IIIB 02/2009 normal
18 66 ♂ MM IgG κ IIA 07/2006 n.d.
19 78 ♂ MM IgG κ IIA 2006 n.d.
20 66 ♀ MM IgG λ IIIA 1997 del13q14; t(4;14)
21 72 ♂ MM IgG κ IIIA 04/1999 n.d.
22 53 ♂ MM IgA λ IIIB 06/2007 n.d.
23 57 ♀ MM IgG κ IA 06/2010 del13q14; t(11;14)
24 59 ♂ MM IgG λ IIIA 04/2013 t(11;14);t(14q32) tri13q14
25 73 ♀ MM IgA κ IIIA 07/2013 n.d.
26 54 ♀ MM IgG λ II 12/2008 n.d.
doi: 10.1371/journal.pone.0084840.t002
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Figure 4.  11C-MET is superior to 18F-FET and 18F-FDG in CD138+-plasma cells.  CD138+-plasma cells were incubated with either
18F-FDG, 18F-FET or 11C-MET for 60 min and intracellular radioactivity was quantified using a gamma-counter. Relative uptake of
background- and decay-corrected samples was expressed as cpm per 1000 cells. Whenever possible, bone marrow samples were
split and one half of the sample was incubated with 18F-FDG, the other with either 18F-FET (patients no 7, 10, 11) or 11C-MET
(patients no. 13, 16, 17, 18, 19, 21, 22, 26). (A) 18F-FDG, 18F-FET and 11C-MET uptake by CD138+ PCs. Data from all samples
analyzed are shown. (B) Direct comparison of 18F-FDG and 11C-MET uptake in split samples. Lines indicate corresponding samples
from one patient.
doi: 10.1371/journal.pone.0084840.g004
Imaging Biomarker for Multiple Myeloma
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Supporting Information
Figure S1.  Free immunoglobulin light chain and Ki-67
expression in selected CD138+-plasma cell samples as a
function of 11C-MET uptake. Levels of free immunoglobulin
light chains in serum and percentage of Ki-67+ cells in bone
marrow biopsies were obtained from routine diagnostic workup
of selected patients (patients no. 13, 16, 17, 18, 19, 21, 22, 26).
Correlation analysis according to Pearson of free
immunoglobulin light chains (r = 0.509; A) or Ki-67 expression
(r = 0.033; B) with 11C-MET uptake and of free immunoglobulin
light chains and Ki-67 (r = 0.124; C) in CD138+-plasma cell
samples is shown.
(DOCX)
Table S1.  Clinical presentation of MGUS vs. MM.
(DOCX)
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